LY2584702

Known as: p70S6K Inhibitor LY2584702 
An orally available inhibitor of p70S6K signaling, with potential antineoplastic activity. p70S6K inhibitor LY2584702 inhibits ribosomal protein S6… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2017
02420142017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
mTORC1 signaling not only plays important physiological roles in the regulation of proliferation and osteogenic differentiation… (More)
Is this relevant?
2017
2017
LTB4 is an inflammatory lipid mediator mainly biosynthesized by leukocytes. Since its implication in inflammatory diseases is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
LY2584702 is an inhibitor of p70 S6 kinase-1 previously developed for the treatment of cancer. In two phase 1 trials in oncology… (More)
Is this relevant?
2017
2017
The safety, pharmacokinetic, and pharmacodynamic effects of LY2584702, a selective inhibitor for p70 S6 serine/threonine protein… (More)
Is this relevant?
2017
2017
RPS6KB1 is the kinase of ribosomal protein S6 which is 70 kDa and is required for protein translation. Although the abnormal… (More)
Is this relevant?
2014
2014
BACKGROUND LY2584702 tosylate (hereafter referred to as LY2584702) is a potent, highly selective adenosine triphosphate (ATP… (More)
Is this relevant?
2014
2014
BACKGROUND LY2584702 tosylate (hereafter referred to as LY2584702) is an oral, selective ATP competitive inhibitor of p70 S6… (More)
Is this relevant?